CN107106873A - 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 - Google Patents

用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 Download PDF

Info

Publication number
CN107106873A
CN107106873A CN201680004801.2A CN201680004801A CN107106873A CN 107106873 A CN107106873 A CN 107106873A CN 201680004801 A CN201680004801 A CN 201680004801A CN 107106873 A CN107106873 A CN 107106873A
Authority
CN
China
Prior art keywords
inhibitor
oxygen
nitrogen
sulphur
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680004801.2A
Other languages
English (en)
Chinese (zh)
Inventor
G.C.哈里曼
R.卡佩勒-利伯曼
W.F.韦斯特林
H.J.哈伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geely De Appollo
Original Assignee
Geely De Appollo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geely De Appollo filed Critical Geely De Appollo
Publication of CN107106873A publication Critical patent/CN107106873A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680004801.2A 2015-01-09 2016-01-08 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 Pending CN107106873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
US62/101,726 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
CN107106873A true CN107106873A (zh) 2017-08-29

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680004801.2A Pending CN107106873A (zh) 2015-01-09 2016-01-08 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗

Country Status (13)

Country Link
US (2) US20180021341A1 (https=)
EP (2) EP3597271A1 (https=)
JP (2) JP2018501276A (https=)
KR (1) KR20170102299A (https=)
CN (1) CN107106873A (https=)
AU (1) AU2016205138A1 (https=)
BR (1) BR112017014341A2 (https=)
CA (1) CA2972919A1 (https=)
EA (2) EA201892625A1 (https=)
HK (2) HK1246232A1 (https=)
MX (1) MX2017008844A (https=)
SG (1) SG11201705361PA (https=)
WO (1) WO2016112305A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
CN109745549A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN110628810A (zh) * 2019-08-13 2019-12-31 浙江大学 一种提高植物光合效率的方法
CN110950884A (zh) * 2018-09-27 2020-04-03 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
WO2020103851A1 (zh) * 2018-11-20 2020-05-28 中国医药研究开发中心有限公司 螺环类化合物及其医药用途
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CN113164498A (zh) * 2018-09-06 2021-07-23 盖尔梅德研究与发展有限公司 用于肝病的治疗的组合疗法
CN116490189A (zh) * 2020-11-17 2023-07-25 伊文蒂瓦公司 用于肝病治疗的联合疗法
CN117396206A (zh) * 2021-06-04 2024-01-12 吉利德科学公司 治疗nash和nafld的化合物

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
KR101974793B1 (ko) 2015-07-06 2019-05-02 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
CA3004796C (en) * 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CN119977993A (zh) 2016-03-02 2025-05-13 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
ES2929758T3 (es) 2016-05-05 2022-12-01 Childrens Hospital Med Ct Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
KR102729404B1 (ko) 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
MA46786A (fr) * 2016-11-10 2019-09-18 Galmed Res And Development Ltd Inhibition de la fibrose chez des patients atteints d'une stéatose hépatique non alcoolique
IL311409A (en) * 2016-11-10 2024-05-01 Galmed Res And Development Ltd Use of Amcol for the treatment of fibrosis
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN108341830B (zh) * 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
CN110431144B (zh) * 2017-03-24 2022-08-05 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
PT3600309T (pt) * 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
WO2018183342A1 (en) * 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
AU2018250614A1 (en) * 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
US11583570B2 (en) * 2017-04-24 2023-02-21 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
US20200129511A1 (en) * 2017-06-19 2020-04-30 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
WO2019015583A1 (en) 2017-07-17 2019-01-24 Nanjing Ruijie Pharmatech Co., Ltd. NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS
WO2019020041A1 (zh) * 2017-07-26 2019-01-31 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CA3089678A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3101274A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11912701B2 (en) 2018-07-16 2024-02-27 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
US20210322324A1 (en) * 2018-08-14 2021-10-21 Avolynt Method for treating primary sclerosing cholangitis
CR20210110A (es) 2018-08-31 2021-05-13 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN113677336B (zh) * 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2020243633A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3995498A4 (en) * 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
CA3148780A1 (en) 2019-07-29 2021-02-04 Bent PFAFFENROT Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
KR102940806B1 (ko) * 2019-08-30 2026-03-20 (주)셀트리온 피오글리타존, L-카르니틴 및 비페닐디메틸카르복실레이트를 포함하는 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
AU2021207236A1 (en) 2020-01-15 2022-08-11 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CN115335055A (zh) * 2020-03-11 2022-11-11 东亚St株式会社 用于预防或治疗非酒精性脂肪性肝炎的药物组合物
AU2021249010B2 (en) 2020-03-30 2024-09-26 Gilead Sciences, Inc. Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US12521375B2 (en) 2020-05-21 2026-01-13 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
CA3214961A1 (en) 2021-03-29 2022-10-06 Gilead Sciences, Inc. Khk inhibitors
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
US20250006331A1 (en) * 2021-08-31 2025-01-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
US20250017938A1 (en) * 2023-06-20 2025-01-16 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
WO2025225969A1 (ko) * 2024-04-22 2025-10-30 연세대학교 원주산학협력단 CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525194A (ja) * 2008-06-20 2011-09-15 キネメッド， インコーポレイテッド 線維性疾患または病態を治療するための組成物
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
AU2014262547A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
MX2015015422A (es) * 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EA201591959A1 (ru) * 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
CN109745549A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CN113164498A (zh) * 2018-09-06 2021-07-23 盖尔梅德研究与发展有限公司 用于肝病的治疗的组合疗法
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN110950884A (zh) * 2018-09-27 2020-04-03 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
WO2020103851A1 (zh) * 2018-11-20 2020-05-28 中国医药研究开发中心有限公司 螺环类化合物及其医药用途
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
CN110628810A (zh) * 2019-08-13 2019-12-31 浙江大学 一种提高植物光合效率的方法
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
CN116490189A (zh) * 2020-11-17 2023-07-25 伊文蒂瓦公司 用于肝病治疗的联合疗法
CN117396206A (zh) * 2021-06-04 2024-01-12 吉利德科学公司 治疗nash和nafld的化合物

Also Published As

Publication number Publication date
JP2018501276A (ja) 2018-01-18
HK1246232A1 (zh) 2018-09-07
JP2020109130A (ja) 2020-07-16
EA201892625A1 (ru) 2019-07-31
EP3242722A4 (en) 2018-07-11
MX2017008844A (es) 2018-03-14
AU2016205138A1 (en) 2017-07-13
US20180021341A1 (en) 2018-01-25
EP3242722A1 (en) 2017-11-15
WO2016112305A1 (en) 2016-07-14
EA201791258A1 (ru) 2017-12-29
US20190381045A1 (en) 2019-12-19
EP3597271A1 (en) 2020-01-22
HK1243369A1 (zh) 2018-07-13
KR20170102299A (ko) 2017-09-08
CA2972919A1 (en) 2016-07-14
BR112017014341A2 (pt) 2018-03-27
SG11201705361PA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
CN107106873A (zh) 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
JP7335056B2 (ja) ビグアナイド組成物および代謝障害を治療する方法
US11963961B2 (en) Combination therapy comprising an ACC inhibitor
JP6581625B2 (ja) 代謝障害を治療するための組成物および方法
US9481642B2 (en) Biguanide compositions and methods of treating metabolic disorders
JP2004525179A (ja) ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置
US9480663B2 (en) Biguanide compositions and methods of treating metabolic disorders
US20090149498A1 (en) Pharmaceutical composition having prokinetic effect
HK40021469A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
HK40024982A (en) Combination therapy comprising an acc inhibitor
EA042749B1 (ru) Композиции метформина и способы лечения расстройств метаболизма глюкозы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243369

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1243369

Country of ref document: HK